Literature DB >> 24363528

Added value of hepatobiliary phase gadoxetic acid-enhanced MRI for diagnosing hepatocellular carcinoma in high-risk patients.

Sith Phongkitkarun1, Kuruwin Limsamutpetch1, Penampai Tannaphai1, Janjira Jatchavala1.   

Abstract

AIM: To determine the added value of hepatobiliary phase (HBP) gadoxetic acid-enhanced magnetic resonance imaging (MRI) in evaluating hepatic nodules in high-risk patients.
METHODS: The institutional review board approved this retrospective study and waived the requirement for informed consent. This study included 100 patients at high risk for hepatocellular carcinoma (HCC) and 105 hepatic nodules that were larger than 1 cm. A blind review of two MR image sets was performed in a random order: set 1, unenhanced (T1- and T2-weighted) and dynamic images; and set 2, unenhanced, dynamic 20-min and HBP images. The diagnostic accuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were compared for the two image sets. Univariate and multivariate analyses were performed on the MR characteristics utilized to diagnose HCC.
RESULTS: A total of 105 hepatic nodules were identified in 100 patients. Fifty-nine nodules were confirmed to be HCC. The diameter of the 59 HCCs ranged from 1 to 12 cm (mean: 1.9 cm). The remaining 46 nodules were benign (28 were of hepatocyte origin, nine were hepatic cysts, seven were hemangiomas, one was chronic inflammation, and one was focal fat infiltration). The diagnostic accuracy significantly increased with the addition of HBP images, from 88.7% in set 1 to 95.5% in set 2 (P = 0.002). In set 1 vs set 2, the sensitivity and NPV increased from 79.7% to 93.2% and from 78.9% to 91.8%, respectively, whereas the specificity and PPV were not significantly different. The hypointensity on the HBP images was the most sensitive (93.2%), and typical arterial enhancement followed by washout was the most specific (97.8%). The multivariate analysis revealed that typical arterial enhancement followed by washout, hyperintensity on T2-weighted images, and hypointensity on HBP images were statistically significant MRI findings that could diagnose HCC (P < 0.05).
CONCLUSION: The addition of HBP gadoxetic acid-enhanced MRI statistically improved the diagnostic accuracy in HCCs larger than 1 cm. Typical arterial enhancement followed by washout and hypointensity on HBP images are useful for diagnosing HCC.
© 2013 Baishideng Publishing Group Co., Limited. All rights reserved.

Entities:  

Keywords:  Gadoxetic acid; Hepatobiliary phase; Hepatocellular carcinoma; Liver; Magnetic resonance imaging

Mesh:

Substances:

Year:  2013        PMID: 24363528      PMCID: PMC3857460          DOI: 10.3748/wjg.v19.i45.8357

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  23 in total

1.  T2-weighted MR imaging in the assessment of cirrhotic liver.

Authors:  Hero K Hussain; Ibrahim Syed; Hanh V Nghiem; Timothy D Johnson; Ruth C Carlos; William J Weadock; Isaac R Francis
Journal:  Radiology       Date:  2004-01-22       Impact factor: 11.105

2.  Experimental hepatic dysfunction: evaluation by MR imaging with Gd-EOB-DTPA.

Authors:  T Murakami; T Kim; M Gotoh; Y Hasuike; N Kato; T Miyazawa; M Monden; H Nakamura
Journal:  Acad Radiol       Date:  1998-04       Impact factor: 3.173

3.  Liver tumor characterization: comparison between liver-specific gadoxetic acid disodium-enhanced MRI and biphasic CT--a multicenter trial.

Authors:  Juha Halavaara; Josy Breuer; Carmen Ayuso; Thomas Balzer; Marie-France Bellin; Lennart Blomqvist; Rick Carter; Luigi Grazioli; Renate Hammerstingl; Alexander Huppertz; Gregor Jung; Denis Krause; Andrea Laghi; Edward Leen; Luciano Lupatelli; Luca Marsili; Julio Martin; E Scott Pretorius; Caroline Reinhold; Michael Stiskal; Alan H Stolpen
Journal:  J Comput Assist Tomogr       Date:  2006 May-Jun       Impact factor: 1.826

4.  Cancer control in Thailand.

Authors:  Vanchai Vatanasapt; Supannee Sriamporn; Patravoot Vatanasapt
Journal:  Jpn J Clin Oncol       Date:  2002-03       Impact factor: 3.019

5.  Fatty metamorphosis of hepatocellular carcinoma: detection with chemical shift gradient-echo MR imaging.

Authors:  J Martín; M Sentís; A Zidan; L Donoso; J Puig; J Falcó; R Bella
Journal:  Radiology       Date:  1995-04       Impact factor: 11.105

6.  Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma.

Authors:  Seong Hyun Kim; Seung Hoon Kim; Jongmee Lee; Min Ju Kim; Yong Hwan Jeon; Yulri Park; Dongil Choi; Won Jae Lee; Hyo K Lim
Journal:  AJR Am J Roentgenol       Date:  2009-06       Impact factor: 3.959

7.  Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma.

Authors:  Alejandro Forner; Ramón Vilana; Carmen Ayuso; Lluís Bianchi; Manel Solé; Juan Ramón Ayuso; Loreto Boix; Margarita Sala; María Varela; Josep M Llovet; Concepció Brú; Jordi Bruix
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

8.  Adenomatous hyperplasia in the vicinity of small hepatocellular carcinoma.

Authors:  A Eguchi; O Nakashima; S Okudaira; S Sugihara; M Kojiro
Journal:  Hepatology       Date:  1992-05       Impact factor: 17.425

Review 9.  Hypointense hepatic lesions depicted on gadobenate dimeglumine-enhanced three-hour delayed hepatobiliary-phase MR imaging: differentiation between benignancy and malignancy.

Authors:  Hye Sun Hwang; Seong Hyun Kim; Tae Yeon Jeon; Dongil Choi; Won Jae Lee; Hyo K Lim
Journal:  Korean J Radiol       Date:  2009-04-22       Impact factor: 3.500

10.  Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions.

Authors:  Renate Hammerstingl; Alexander Huppertz; Josy Breuer; Thomas Balzer; Anthony Blakeborough; Rick Carter; Lluis Castells Fusté; Gertraud Heinz-Peer; Werner Judmaier; Michael Laniado; Riccardo M Manfredi; Didier G Mathieu; Dieter Müller; Koenraad Mortelè; Peter Reimer; Maximilian F Reiser; Philip J Robinson; Kohkan Shamsi; Michael Strotzer; Matthias Taupitz; Bernd Tombach; Gianluca Valeri; Bernhard E van Beers; Thomas J Vogl
Journal:  Eur Radiol       Date:  2007-12-06       Impact factor: 5.315

View more
  12 in total

Review 1.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047

2.  Extracellular contrast agent-enhanced MRI: 15-min delayed phase may improve the diagnostic performance for hepatocellular carcinoma in patients with chronic liver disease.

Authors:  Si Eun Lee; Chansik An; Shin Hye Hwang; Jin-Young Choi; Kyunghwa Han; Myeong-Jin Kim
Journal:  Eur Radiol       Date:  2017-11-13       Impact factor: 5.315

3.  Respiratory Motion-Resolved Compressed Sensing Reconstruction of Free-Breathing Radial Acquisition for Dynamic Liver Magnetic Resonance Imaging.

Authors:  Hersh Chandarana; Li Feng; Justin Ream; Annie Wang; James S Babb; Kai Tobias Block; Daniel K Sodickson; Ricardo Otazo
Journal:  Invest Radiol       Date:  2015-11       Impact factor: 6.016

Review 4.  Recent Advances in the Imaging Diagnosis of Hepatocellular Carcinoma: Value of Gadoxetic Acid-Enhanced MRI.

Authors:  Ijin Joo; Jeong Min Lee
Journal:  Liver Cancer       Date:  2015-12-18       Impact factor: 11.740

5.  Performance of adding hepatobiliary phase image in magnetic resonance imaging for detection of hepatocellular carcinoma: a meta-analysis.

Authors:  Jielin Pan; Wenjuan Li; Lingjing Gu; Chaoran Liu; Ke Zhang; Guobin Hong
Journal:  Eur Radiol       Date:  2022-05-17       Impact factor: 5.315

Review 6.  Magnetic resonance imaging for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.

Authors:  Tin Nadarevic; Agostino Colli; Vanja Giljaca; Mirella Fraquelli; Giovanni Casazza; Cristina Manzotti; Davor Štimac; Damir Miletic
Journal:  Cochrane Database Syst Rev       Date:  2022-05-06

Review 7.  JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan.

Authors:  Masatoshi Kudo; Osamu Matsui; Namiki Izumi; Hiroko Iijima; Masumi Kadoya; Yasuharu Imai; Takuji Okusaka; Shiro Miyayama; Kaoru Tsuchiya; Kazuomi Ueshima; Atsushi Hiraoka; Masafumi Ikeda; Sadahisa Ogasawara; Tatsuya Yamashita; Tetsuya Minami; Koichiro Yamakado
Journal:  Liver Cancer       Date:  2014-10       Impact factor: 11.740

8.  ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents.

Authors:  E Neri; M A Bali; A Ba-Ssalamah; P Boraschi; G Brancatelli; F Caseiro Alves; L Grazioli; T Helmberger; J M Lee; R Manfredi; L Martì-Bonmatì; C Matos; E M Merkle; B Op De Beeck; W Schima; S Skehan; V Vilgrain; C Zech; C Bartolozzi
Journal:  Eur Radiol       Date:  2015-07-21       Impact factor: 5.315

9.  Diagnostic Accuracy of Gd-EOB-DTPA for Detection Hepatocellular Carcinoma (HCC): A Comparative Study with Dynamic Contrast Enhanced Magnetic Resonance Imaging (MRI) and Dynamic Contrast Enhanced Computed Tomography (CT).

Authors:  Massimo Imbriaco; Serena De Luca; Milena Coppola; Mario Fusari; Michele Klain; Marta Puglia; Pierpaolo Mainenti; Raffaele Liuzzi; Simone Maurea
Journal:  Pol J Radiol       Date:  2017-02-01

10.  Comparison of LI-RADS v.2017 and ESGAR Guidelines Imaging Criteria in HCC Diagnosis Using MRI with Hepatobiliary Contrast Agents.

Authors:  Grzegorz Rosiak; Joanna Podgorska; Edyta Rosiak; Andrzej Cieszanowski
Journal:  Biomed Res Int       Date:  2018-07-15       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.